Study on prescription medication rules of modern Chinese materia medica compound in treating chronic migraine based on data mining
LIU Zhen1 DU Shan2 GU Jinghui3 LI Weidong4 LIU Yan5▲
1.Department of Emergency, Beijing First Hospital of Integrated Chinese and Western Medicine, Beijing 100026, China;
2.Department of Encephalopathy, Beijing First Hospital of Integrated Chinese and Western Medicine, Beijing 100026, China;
3.Department of Traditional Chinese Medicine, Beijing First Hospital of Integrated Chinese and Western Medicine, Beijing 100026, China;
4.Office of Academic Research, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China;
5.Department of Encephalopathy, Beijing Chaoyang District Hospital of Traditional Chinese Medicine, Beijing 100020, China
Abstract:Objective To explore the prescription medication rules of modern Chinese materia medica compound in treating chronic migraine by using modern information technology. Methods Literatures on Chinese materia medica compound therapy for chronic migraine were retrieved from VIP Information Chinese Science and Technology Journal database, Chinese National Knowledge Infrastructure, and Wanfang Medical Network database from January 2013 to December 2020, and the literatures meeting the inclusion and exclusion criteria were preprocessed. Excel 2019 was used to conduct statistical analysis on the frequency of use, efficacy categories, and nature and flavour and channel tropism of Chinese materia medica in the database. SPSS Modeler 18.0 and SPSS Statistics 20 were used for association rule analysis and cluster analysis respectively. Results A total of 236 literatures meeting the standard were screened, involving 255 groups of prescriptions, 165 Chinese materia medica were recorded, and 36 Chinese materia medica with high frequency (frequency ≥27 times) were screened, such as Chuanxiong Rhizoma, Glycyrrhizae Radix Et Rhizoma, Paeoniae Radix Alba, Gastrodiae Rhizoma, etc. According to the statistics of high-frequency Chinese materia medica, drug classification were mainly drugs for promoting blood circulation for removing blood stasis, suppressing hyperactive liver for calming endogenous wind, and invigorating qi and blood; drug properties were mainly warm drugs; drug tastes were mainly pungent drugs; channels tropism were mainly liver and spleen channels. The association rule analysis and cluster analysis of high frequency Chinese materia medica formed 23 couplet medicines combinations and five cluster combinations respectively. Conclusion Chronic migraine drugs are mainly drugs for promoting blood circulation for removing blood stasis, suppressing hyperactive liver for calming endogenous wind, and invigorating qi and blood, most of the selection of warm nature, taste pungent, return to the liver and spleen channel drugs.
刘振1 杜珊2 顾景辉3 李卫东4 刘燕5▲. 基于数据挖掘的现代中药复方治疗慢性偏头痛的组方用药规律研究[J]. 中国医药导报, 2022, 19(16): 11-15.
LIU Zhen1 DU Shan2 GU Jinghui3 LI Weidong4 LIU Yan5▲. Study on prescription medication rules of modern Chinese materia medica compound in treating chronic migraine based on data mining. 中国医药导报, 2022, 19(16): 11-15.
[1] Arnold M. Headache classification committee of the international headache society (IHS) the international classification of headache disorders [J]. Cephalalgia,2018,38(1):1-211.
[2] Stovner LJ,Nichols E,Steiner TJ,et al. Global,regional,and national burden of migraine and tension-type headache,1990—2016:a systematic analysis for the Global Burden of Disease Study 2016 [J]. Lancet Neurol,2018,17(11):954-976.
[3] Natoli JL,Manack A,Dean B,et al. Global prevalence of chronic migraine:A systematic review [J]. Cephalalgia,2010,30(5):599-609.
[4] 中国医师协会神经内科医师分会疼痛与感觉障碍学组.偏头痛与抑郁障碍共病诊治中国专家共识[J].中国疼痛医学杂志,2020,26(12):881-890.
[5] Yao C,Wang Y,Wang L,et al. Burden of headache disorders in China,1990—2017:findings from the Global Burden of Disease Study 2017[J]. J Headache Pain,2019,20(1):102.
[6] 姚刚,曹河圻,朱元贵.中国头痛基础研究的现状与挑战[J].中华神经医学杂志,2020,19(5):433-438.
[7] 中华医学会疼痛学分会头面痛学组,中国医师协会神经内科医师分会疼痛和感觉障碍专委会.中国偏头痛防治指南[J].中国疼痛医学杂志,2016,22(10):721-727.
[8] 鲁文先,宋维伟,陈金波.偏头痛药物治疗现状[J].中国医学创新,2021,18(15):185-188.
[9] 杨心怡,张菁,李南洋,等.偏头痛药物预防及治疗新进展[J].中国临床药理学与治疗学,2020,25(12):1429-1435.
[10] 肖许珍,杨文明.杨文明运用疏风豁痰、化瘀通络法治疗偏头痛经验[J].中医杂志,2021,62(23):2042-2045.
[11] 徐榛敏,贾敏,梁晓,等.偏头痛中医临床实践指南(征求意见稿)[J].中国中药杂志,2020,45(21):5057-5067.
[12] 付国静,鲁喦,张允岭,等.以偏头痛为例分析中医临床实践指南中常用方药的遴选原则[J].中国中药杂志,2020, 45(21):5103-5109.
[13] 韦紫君,李萌青,张云云.中医治疗偏头痛的临床研究进展[J].中西医结合心脑血管病杂志,2020,18(17):2804-2809.
[14] 吴江.神经病学[M].北京:人民卫生出版社,2018.
[15] 郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002.
[16] 钟赣生.中药学[M].北京:中国中医药出版社,2013.
[17] 吴嘉瑞,金燕萍,张冰,等.基于关联规则与熵聚类的化瘀类中成药组方规律研究[J].中国医药导报,2015,12(13):117-119,123.
[18] 贾彩霞,陈建新,高阔,等.川芎治疗心力衰竭的网络药理学研究[J].世界中医药,2020,15(8):1093-1097.
[19] 张晓娟,张燕丽,左冬冬.川芎的化学成分和药理作用研究进展[J].中医药信息,2020,37(6):128-133.
[20] 李芊,吴效科.川芎化学成分及药理作用研究新进展[J].化学工程师,2020,34(1):62-64.
[21] 张林珍,刘光珍,王爱梅,等.虫类药治疗顽固性头痛刍议[J].中西医结合心脑血管病杂志,2020,18(4):696-697.
[22] 李琰.“久病入络”与慢性偏头痛辨治[J].实用中医内科杂志,2018,32(9):1-4.
[23] 李盼,陈雨微,丁丽琴,等.辛味中药在治疗消渴证中的应用价值及中药五味理论现代研究的思考[J].中草药,2019,50(22):5577-5583.
[24] 马继征,刘绍能.辛温药在血瘀证治疗中的应用探析[J].中医药信息,2010,27(3):87-88.
[25] 冯秀芝,吴继雷,任艳玲.温里药之辛味作用内涵探析[J].中国医药导报,2021,18(26):133-136.
[26] 赵丹,刘长玉.于志强基于肝脾相关理论辨治偏头痛经验撷粹[J].江苏中医药,2017,49(7):15-17.
[27] 宁鲁宁,刘德山.刘德山教授从肝脾论治神经血管性头痛经验[J].四川中医,2018,36(8):3-5.
[28] 刘燕,李春胜,秦丽玲.偏头痛的中医药治疗研究进展[J].中国中医急症,2019,28(9):1675-1678.